Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-022215
Filing Date
2024-03-13
Accepted
2024-03-13 16:59:10
Documents
16
Period of Report
2023-12-15
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 TO FORM 8-K ea0201700-8ka3_onconetix.htm   iXBRL 8-K/A 27427
2 CONSENT OF BDO AG ea020170001ex23-1_onconetix.htm EX-23.1 4651
3 GRAPHIC ex23-1_001.jpg GRAPHIC 4103
  Complete submission text file 0001213900-24-022215.txt   220035

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE onco-20231215.xsd EX-101.SCH 3042
5 XBRL PRESENTATION FILE onco-20231215_pre.xml EX-101.PRE 22377
6 XBRL LABEL FILE onco-20231215_lab.xml EX-101.LAB 34240
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0201700-8ka3_onconetix_htm.xml XML 5161
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41294 | Film No.: 24746798
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)